Clinical trials: Clostridium Difficile-Associated Diarrhea
Clostridium Difficile Infection, Antibiotic Associated Diarrhea
Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea
Antibiotic-associated diarrhea (AAD) and particularly Clostridium difficile-Infection (CDI) are the most common causes of healthcare associated infectious diarrhea.
- Trial name
- NCT01972932
- Testing
- Bio K+® 2 capsules orally (or via nasogastric tube)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Bio-K Plus International Inc.
Diarrhea Due to Clostridium Difficile
Host Immune Response to Clostridium Difficile Infection (ICD)
Clostridium difficile is responsible for up to 25% of reported antibiotic associated diarrhea cases and virtually all cases of pseudomembranous colitis (PMC). The clinical spectrum of C.
- Trial name
- ICD (NCT02440438)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Clostridium Difficile
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain
The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized in the nephrology and transplantation ward.
- Trial name
- NCT03368105
- Testing
- Prevention of C. difficile infections using LP299v strain
- Volunteers
- 300 people
- Sponsor
- Medical University of Silesia
Clostridium; Difficile, As Cause of Disease Classified Elsewhere, Clostridium Difficile Diarrhea
Advantages and Disadvantages of TOXCLEAN As Add on Treatment to SOC in Patients with Clostridium Difficile-associated Diarrhea
This is a single center, randomized, exploratory clinical investigation that will evaluate the safety and efficacy of Toxclean (ABResearch srl) as add on treatment to Standard therapy in 24 patients with recurrent CDAD.
- Trial name
- NCT06839209
- Testing
- Toxclean 1g
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- ABResearch S.r.l.
Clostridium Difficile Associated Diarrhea (CDAD)
A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)
This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of oral doses of surotomycin (CB-183,315) administered for 14 consecutive days in healthy males and females.
- Trial name
- NCT02835118
- Testing
- Surotomycin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Clostridium Difficile-associated Diarrhea (CDAD)
IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff
In this trial, eligible patients will be randomly assigned to receive a single dose of 400 mg/kg of IVIG or a normal saline infusion as placebo over 4-6 hours, in addition to their usual medications for CDAD.
- Trial name
- NCT00177970
- Testing
- intravenous immunoglobulin G (IVIG)
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Pittsburgh
Diarrhea
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)
The purpose of this study is to investigate the safety and perform preliminary clinical evaluation in patients with mild to moderate CDAD.
- Trial name
- NCT00097422
- Testing
- OPT-80
- Where
- United States
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diarrhea, Clostridium Infections
Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
The purpose of this study is to evaluate the efficacy and safety of Bio-K + CL1285 versus placebo in the prevention of antibiotic-associated diarrhea in hospitalized adult patients.
- Trial name
- NCT00328263
- Testing
- Lactobacillus acidophilus CL1285 and Lactobacillus casei
- Where
- 8 sites in Canada
- Volunteers
- 472 people
- Sponsor
- Bio-K Plus International Inc.
Diarrhea, Clostridium Difficile
Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly
The purpose of this study is to determine whether Lactobacillus acidophilus/rhamnosus complex is effective in the prevention of antibiotic-associated diarrhea (AAD) in the elderly.
- Trial name
- NCT01048567
- Testing
- Lactobacillus acidophilus/rhamnosus
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Vancouver Island Health Authority
Clostridium Difficile-Associated Diarrhea (CDAD)
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)
The objective of this study is to demonstrate the efficacy and safety of Fidaxomicin versus placebo for prophylaxis against Clostridium difficile-Associated Diarrhea (CDAD) in adult participants undergoing hematopoietic stem cell…
- Trial name
- DEFLECT-1 (NCT01691248)
- Testing
- fidaxomicin
- Volunteers
- 611 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Clostridium Difficile Infection
Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
Clostridium difficile associated diarrhoea is an important cause of morbidity in patients treated with antibiotics, especially in hospital. Clinical relapse occurs after up to 30% of initially successful treatments for colitis.
- Trial name
- RAPID (NCT01670149)
- Testing
- Rifaximin
- Where
- United Kingdom
- Volunteers
- 151 people
- Sponsor
- University of Nottingham
Clostridium Difficile-associated Diarrhea
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of fidaxomicin in pediatric subjects with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT01591863
- Testing
- fidaxomicin
- Volunteers
- 38 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Antibiotic Associated Diarrhoea
Bovine Lactoferrin and Antibiotic-associated Diarrhoea.
This prospective, randomized, parallel-group, double blind, single-center study is to be conducted in the Medical University of Warsaw Public Paediatric Teaching Hospital in following departments: Department of Paediatric…
- Trial name
- BLAAD (NCT02626104)
- Testing
- Bovine lactoferrin, Maltodextrin
- Where
- Poland
- Volunteers
- 156 people
- Sponsor
- Medical University of Warsaw
Diarrhea
Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease
The study will evaluate if administration of probiotic Culturelle (Lactobacillus Rhamnosus GG) along with antibiotics can help decrease the occurrence of diarrhea caused by antibiotics as well as Clostridium difficile Diarrhea.
- Trial name
- NCT02076438
- Testing
- Probiotics
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Clostridium Difficile-Associated Diarrhea
Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies
This clinical study is designed to evaluate the safety and efficacy of oral administration of the food additive colostrum derived antibodies to Clostridium difficile for prevention of Clostridium difficile associated disease…
- Trial name
- NCT00747071
- Testing
- Colostrum
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Clostridium Infections
MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation
The registry collects cases of patients received fecal microbiota transplantation (FMT) due to Clostridium difficile associated diarrhea (CDAD). The main objective of this study is to analyze the safety and effectiveness of FMT.
- Trial name
- MicroTrans (NCT02681068)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University of Cologne
Clostridium Difficile Infection Recurrence
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy.
- Trial name
- CDI-SCOPE (NCT05831189)
- Testing
- RBX2660
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ferring Pharmaceuticals
Clostridium Difficile Infection
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
The objective of this Phase IIa study is to assess the safety, tolerability, and efficacy of incremental doses of MGB-BP-3 in patients with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT03824795
- Testing
- MGB-BP-3
- Where
- 9 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- MGB Biopharma Limited
Enterocolitis, Pseudomembranous Colitis
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
The purpose of this study is to determine whether dietary supplementation with Lactobacillus GG will reduce the rate of failure or relapse following treatment of CDAD with metronidazole.
- Conditions
- Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
- Trial name
- NCT00304863
- Testing
- Lactobacillus GG
- Where
- United States
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile Infection
Fecal Microbiota Transplantation for C Diff Infection
The objective of this study is to provide treatment with Fecal Microbiota Transplantation (FMT) to patients with recurrent or refractory Clostridium difficile infection (CDI).
- Trial name
- NCT01905709
- Testing
- Human fecal matter
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Englewood Hospital and Medical Center